ARTICLE | Financial News
CIRM awards $44M in grants
June 30, 2017 10:22 PM UTC
The California Institute for Regenerative Medicine awarded more than $44 million over four grants to develop stem cell therapies to treat stroke, a fetal blood disorder and acute myelogenous leukemia (AML).
CIRM awarded $20 million to cell therapy company SanBio Co. Ltd. (Tokyo:4592) to support the Phase IIb ACTIsSIMA trial of stem cell therapy SB623 to treat chronic motor deficit following a stroke. SanBio began ACTIsSIMA in 2016 and expects data in 2019. SB623 consists of bone marrow-derived cells that are transfected with a plasmid construct carrying the intracellular domain of notch 1 (NOTCH1)...